TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152982

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.
Study: NCT02817750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)
Description: zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)
Description: zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
Study: NCT02614586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.
Study: NCT00520936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
Study: NCT03604380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
Study: NCT01996293

Intervention type: DRUG
Intervention: lamotrigine
Description: Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
Study: NCT01523353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: 4 week personalised exercise program on a static cycle. Supervised in a hospital environment
Study: NCT02123121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol 1000 mg/day
Description: Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol 1500 mg/day
Description: Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable cellulose
Description: Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All groups
Description: All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All groups
Description: All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: All groups
Description: All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
Study: NCT04348773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Dehydration of the natural tooth by tooth isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehydration
Description: Rehydration
Study: NCT00763672

Intervention type: OTHER
Group type: OTHER
Intervention: Transmission of sFlt-1 results to the investigator
Description: Transmission of sFlt-1 results by the laboratory to the investigator

Intervention type: OTHER
Group type: OTHER
Intervention: No transmission of the sFlt-1 results to the investigator
Description: The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
Study: NCT02250170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
Study: NCT03817788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phosphate
Description: All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
Study: NCT03222960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propolis-containing toothpaste
Description: participants will use propolis-containing toothpaste for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste
Description: participants will use Fluoride-containing toothpaste for 6 months
Study: NCT00541593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Pseudocystgastrostomy
Description: An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
Study: NCT00351806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erigeron breviscapus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hua tuo zai zao wan (a herbal medicine pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound stroke herbal medicine (8 herbal)
Study: NCT02050451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus®

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Study: NCT05058118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 50mg、250mg、500mg、1000mg、1500mg、2000mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty bottle
Study: NCT00797706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHRONSEAL
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHRONSEAL
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHRONSEAL
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
Study: NCT00655304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometheus (R) liver support dialysis
Description: 6-8 hours of dialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVVHDF (Continuously Veno-Venous Hemodiafiltration)
Description: 6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
Study: NCT04617106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
Study: NCT04013165

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village-based intervention
Description: 1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults.
Study: NCT01655940

Intervention type: DEVICE
Intervention: Somanetics cerebral oximeter
Description: Somanetics cerebral oximeter

Intervention type: DEVICE
Intervention: CASMED cerebral oximeter
Description: CASMED cerebral oximeter
Study: NCT00560794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab (MT103)
Description: Administered by continuous intravenous (CIV) over 4 weeks per cycle
Study: NCT03879954

Intervention type: DEVICE
Group type: OTHER
Intervention: Catetherization approach
Description: Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization

Intervention type: DEVICE
Group type: OTHER
Intervention: Catetherization approach
Description: Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
Study: NCT02092467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Oral tablet, 10 mg BID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe, 40 mg subcutaneous injection, every other week
Study: NCT02394262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Coronary CT-angiography
Description: Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assesment of biomarkers involved in atherothrombosis
Description: Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
Study: NCT03702985

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 400mg/m2 per week
Study: NCT02241629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo of levo phencynonate hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo of levo phencynonate hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo phencynonate hydrochloride
Description: levo phencynonate hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo phencynonate hydrochloride
Description: levo phencynonate hydrochloride
Study: NCT00598104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study: NCT04437810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: - Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: standard medical therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Treatment
Description: standard medical therapy
Study: NCT03157843

Intervention type: DRUG
Intervention: low-molecular-weight heparin
Study: NCT03647748

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: A modified device utilizing a pigtail connector to bypass active treatment.
Study: NCT00880607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Epidural Morphine
Description: DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
Study: NCT00196807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
Study: NCT00789724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg daily subcutaneous injection for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
Study: NCT04281836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive breathing awareness through use of audio and visual virtual technology aid
Description: Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive breathing awareness without use of audio or visual virtual reality
Description: Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
Study: NCT04203108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: In both groups, MMF will be administrated at a dose of 1.0g/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: In both groups, MMF will be administrated at a dose of 1.0g/d.
Study: NCT02116361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA injected into protocol-specified areas on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA injected into protocol-specified areas on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into protocol-specified areas on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into protocol-specified areas on Day 1.
Study: NCT02092467

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Pre-filled syringe, 50 mg subcutaneous injection, every week
Study: NCT05482555

Intervention type: PROCEDURE
Intervention: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
Description: Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).

Intervention type: PROCEDURE
Intervention: Surgical cut-down and arterial puncture under direct vision
Description: Surgical cut-down and arterial puncture under direct vision.
Study: NCT00067626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chromium
Description: 500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chromium
Description: 500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
Study: NCT01607073

Intervention type: DRUG
Group type: OTHER
Intervention: Verapamil
Description: Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study.
Study: NCT04123171

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging studies
Description: Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
Study: NCT03401476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate Tablets
Study: NCT00744640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, oxaliplatin, capecitabine
Description: gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
Study: NCT02446860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.